Polymorphism of DNA methyltransferase 3B ?49C/T and cancer risk: a meta-analysis

详细信息    查看全文

• 作者：Jing Zhu (1) (2)
  Songtao Du (1)
  Jiaqi Zhang (1)
  Yingnan Wang (1)
  Qiaoling Wu (1)
  Jixiang Ni (1) (2)
  
• 关键词：DNMT3B ; Polymorphism ; Cancer ; Meta ; analysis
• 刊名：Medical Oncology
• 出版年：2015
• 出版时间：January 2015
• 年：2015
• 卷：32
• 期：1
• 全文大小：744 KB
• 参考文献：1. Bheemanaik S, Reddy YV, Rao DN. Structure, function and mechanism of exocyclic DNA methyltransferases. Biochem J. 2006;399:177-0. CrossRef
  2. Xie S, et al. Cloning, expression and chromosome locations of the human DNMT3 gene family. Gene. 1999;236:87-5. CrossRef
  3. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21:163-. CrossRef
  4. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247-7. CrossRef
  5. Robertson KD, et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and over expression in tumors. Nucleic Acids Res. 1999;27:2291-. CrossRef
  6. Belinsky SA, Nikula KJ, Baylin SB, Issa PJ. Increased cytosine DNA methyltransferase activity is target-cell-specific and an early event in lung cancer. Proc Natl Acad Sci. 1996;93:4045-0. CrossRef
  7. Nagai M, Nakamura A, Makino R, Mitamura K. Expression of DNA (5-cytosin)-methyltransferases (DNMTs) in hepatocellular carcinomas. Hepatol Res. 2003;26:186-1. CrossRef
  8. Robertson KD, Keyomarsi K, Gonzales FA, Velicescu M, Jones PA. Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. Nucleic Acids Res. 2000;28:2108-3. CrossRef
  9. Wang L, et al. Polymorphism in DNMT3B6 promoter region and lung cancer risk. Proc Am Assoc Cancer Res. 2001;42:863.
  10. Shen H, et al. A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res. 2002;62:4992-.
  11. Bao Q, et al. Genetic variation in the promoter of DNMT3B is associated with the risk of colorectal cancer. Int J Colorectal Dis. 2011;9:1107-2. CrossRef
  12. Fan H, Zhang F, Hu J, Liu D, Zhao Z. Promoter polymorphisms of DNMT3B and the risk of colorectal cancer in Chinese: a case–control study. J Exp Clin Cancer Res. 2008;27:24. CrossRef
  13. Jones JS, et al. DNMT3b polymorphism and hereditary nonpolyposis colorectal cancer age of onset. Cancer Epidemiol Biomark Prev. 2006;15:886-1. CrossRef
  14. Karpinski P, et al. Polymorphisms in methyl-group metabolism genes and risk of sporadic colorectal cancer with relation to the CpG island methylator phenotype. Cancer Epidemiol. 2010;34:338-4. CrossRef
  15. de Vogel S, et al. Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG Island hypermethylation in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:3086-6. CrossRef
  16. Iacopetta B, et al. The MTHFR C677T and ΔDNMT3B C ?49T polymorphisms confer different risks for right and left-sided colorectal cancer. Int J Cancer. 2009;125:84-0. CrossRef
  17. Reeves SG, et al. The ?49C>T SNP within the ΔDNMT3B gene, is not associated with early disease onset in hereditary non-polyposis colorectal cancer. Cancer Lett. 2008;265:39-4. CrossRef
  18. Aung PP, et al. No evidence of correlation between the single nucleotide polymorphism of DNMT3B promoter and gast
• 作者单位：Jing Zhu (1) (2)
  Songtao Du (1)
  Jiaqi Zhang (1)
  Yingnan Wang (1)
  Qiaoling Wu (1)
  Jixiang Ni (1) (2)
  
  1. Department of Respiratory and Critical Care Medicine, The First People’s Hospital of Yichang, 2# Jiefang Road, Yichang, 443000, Hubei Province, China
  2. Department of Respiratory and Critical Care Medicine, Renmin Hospital of Three Gorges University, Yichang, 443000, China
  
• ISSN：1559-131X

文摘

Published data on the association between DNA methyltransferase (DNMT) 3B ?49C/T polymorphism and cancer risk remain inconclusive. To derive a more precise estimation for this association, we performed a meta-analysis of 5,903 cancer cases and 8,132 controls from 22 published case–control studies. We used odds ratios (ORs) with 95?% confidence intervals (CIs) to assess the strength of the association. Our meta-analysis suggested that DNMT3B ?49C/T polymorphism was associated with the risk of head and neck cancer under heterozygote comparison (OR 0.73, 95?% CI 0.59-.90) and dominant model (OR 1.75, 95?% CI 0.62-.92), although no evidence of association between DNMT3B ?49C/T polymorphism and cancer risk was observed as we compared in the pooled analyses (homozygote comparison: OR 0.96, 95?% CI 0.86-.09; heterozygote comparison: OR 1.07, 95?% CI 0.86-.32; dominant model: OR 1.03, 95?% CI 0.85-.25; recessive model: OR 0.93, 95?% CI 0.8-.08). More studies are needed to detect DNMT3B ?49C/T polymorphism and its association with cancer in different ethnic populations incorporated with environment exposures in the susceptibility of different kinds of cancer.